 |
|
Nonlinear Progression of Parkinson Disease as Determined by Serial Positron Emission Tomographic Imaging of Striatal Fluorodopa F 18 Activity
Ruediger Hilker, MD;
Katherine Schweitzer, MD;
Silke Coburger, PhD;
Mehran Ghaemi, MD;
Simon Weisenbach, MD;
Andreas H. Jacobs, MD;
Jobst Rudolf, MD;
Karl Herholz, MD;
Wolf-Dieter Heiss, MD
Arch Neurol. 2005;62:378-382.
Background The investigation of disease progression provides important information on the dynamics of cell death in Parkinson disease (PD).
Objective To determine the progression of dopaminergic impairment in PD with the use of positron emission tomography (PET).
Design Longitudinal prospective cohort study with a follow-up period of 64.5 ± 22.6 months (mean ± SD).
Setting University hospital.
Patients A consecutive sample of patients with PD (N = 31; age at symptom onset, 53.6 ± 11.3 years) with a wide range of symptom duration and severity at the time of study entry.
Interventions Investigation by serial fluorodopa F 18 ([18F]fluorodopa) PET as a marker for striatal dopaminergic function.
Main Outcome Measures Changes in caudate and putaminal [18F]fluorodopa influx constant (Ki) values.
Results In patients with PD, the decline rate of putaminal [18F]fluorodopa Ki correlated inversely with disease duration before study inclusion (r = –0.46, P = .01) and positively with baseline Ki values (r = 0.44, P = .01), indicating a negative exponential loss of dopamine neurons. Annual disease progression rates ranged from 4.4% in the caudate nucleus to 6.3% in the putamen. A mean preclinical period of 5.6 ± 3.2 years was calculated with symptom onset at a putaminal Ki threshold of 69% from controls. Assuming nonlinear progression kinetics, the required sample size to prove neuroprotection with the use of [18F]fluorodopa PET was found to increase strongly with the preceding symptom duration of study subjects.
Conclusion These data suggest that the neurodegenerative process in PD follows a negative exponential course and slows down with increasing symptom duration, contradicting the long-latency hypothesis of PD.
Author Affiliations: Departments of Neurology (Drs Hilker, Schweitzer, Ghaemi, Jacobs, Rudolf, Herholz, and Heiss) and Medical Statistics, Informatics, and Epidemiology (Dr Coburger), University of Cologne, Cologne, Germany; and Max-Planck-Institute for Neurological Research, Cologne (Drs Weisenbach and Heiss).
RELATED ARTICLE
Progression of Parkinson Disease: Are We Making Progress in Charting the Course?
Joseph Jankovic
Arch Neurol. 2005;62(3):351-352.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Gender differences in Parkinson's disease
Haaxma et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:819-824.
ABSTRACT
| FULL TEXT
Treatment Options in the Modern Management of Parkinson Disease
Schapira
Arch Neurol 2007;64:1083-1088.
FULL TEXT
Changes in network activity with the progression of Parkinson's disease
Huang et al.
Brain 2007;130:1834-1846.
ABSTRACT
| FULL TEXT
Etiology of Parkinson's disease
Schapira
Neurology 2006;66:S10-S23.
ABSTRACT
| FULL TEXT
Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra.
Greffard et al.
Arch Neurol 2006;63:584-588.
ABSTRACT
| FULL TEXT
Progression of motor impairment and disability in Parkinson disease: A population-based study
Alves et al.
Neurology 2005;65:1436-1441.
ABSTRACT
| FULL TEXT
Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease
Borghammer et al.
Arch Neurol 2005;62:1480-1480.
FULL TEXT
Progression of Parkinson Disease: Are We Making Progress in Charting the Course?
Jankovic
Arch Neurol 2005;62:351-352.
FULL TEXT
|
